AEON — AEON Biopharma, Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1837607 ·
Last close
$0.29
Market Cap
$12.94M
52W High
$1.03
52W Low
$0.22
ADV30
2,584,879
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -5,937,000 | -11,793,000 | 8,630,000 | 6,243,000 | 25,382,000 |
| Dec 2025 | 0 | — | -5,501,000 | -37,137,000 | 5,560,000 | 3,006,000 | 60,587,000 |
| Sep 2025 | 0 | — | -2,530,000 | -4,538,000 | 8,734,000 | 5,927,000 | 28,606,000 |
| Jun 2025 | 0 | — | -4,322,000 | -6,642,000 | 11,662,000 | 8,439,000 | 27,514,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-12,035,000
Investing CF
$0
Financing CF
$7,832,000
CapEx
$-4,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$1.00
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-482,612,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-18,290,000
Pretax Income TTM
$-60,110,000
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -16,302,000 | -39,222,000 | 5,560,000 | 60,587,000 | — | -17,308,000 |
| Dec 2024 | 0 | -27,824,000 | 42,005,000 | 3,142,000 | 31,711,000 | — | -20,292,000 |
| Dec 2023 | — | — | — | 6,845,000 | 159,889,000 | — | — |
| Dec 2022 | 0 | -48,429,000 | -52,556,000 | 10,778,000 | 281,191,000 | — | -35,584,000 |
| Dec 2021 | 0 | -36,881,000 | -55,637,000 | — | — | — | -28,433,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-33,832,000
OpCashFlow TTM
$0
Assets (Latest)
$3,142,000
Forward EPS
$-0.69
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BIOE | Bio Essence Corp | $12.64M | $0.27 | — |
| ANEB | Anebulo Pharmaceuticals, Inc. | $13.46M | $0.33 | — |
| BLRX | BioLineRx Ltd. | $12.27M | $2.82 | — |
| TPST | Tempest Therapeutics, Inc. | $13.68M | $0.86 | — |
| PTN | PALATIN TECHNOLOGIES INC | $13.70M | $7.70 | — |
News headlines (Yahoo Finance, 1h cache)
Humana upgraded, Las Vegas Sands downgraded: Wall Street's top analyst calls
2026-07-30 13:38 · Yahoo
AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding
2026-07-14 12:00 · Yahoo
AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society
2026-06-04 11:00 · Yahoo
Cervical Dystonia Market to Witness Robust Growth During the Forecast Period (2026-2036) Driven by the Expanding Therapeutic Options | DelveInsight
2026-06-02 14:01 · Yahoo
Why You Might Be Interested In Aeon Co. (M) Bhd. (KLSE:AEON) For Its Upcoming Dividend
2026-05-25 00:02 · Yahoo
AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-14 20:05 · Yahoo
AEON Biopharma Sets Annual Shareholder Meeting
2026-04-24 20:05 · Yahoo
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
2026-04-03 20:10 · Yahoo
AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards
2026-04-03 20:05 · Yahoo
AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program
2026-03-30 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.